Compare C & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | C | AZN |
|---|---|---|
| Founded | 1812 | 1992 |
| Country | United States | United Kingdom |
| Employees | 226000 | 96100 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.2B | 316.4B |
| IPO Year | N/A | N/A |
| Metric | C | AZN |
|---|---|---|
| Price | $132.64 | $182.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 1 |
| Target Price | ★ $134.94 | N/A |
| AVG Volume (30 Days) | ★ 7.5M | 1.8M |
| Earning Date | 04-14-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.88% | 1.73% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.26 | $10.34 |
| Revenue Next Year | $3.63 | $6.43 |
| P/E Ratio | ★ $16.63 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $76.11 | $68.62 |
| 52 Week High | $135.83 | $212.71 |
| Indicator | C | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 61.74 | 46.87 |
| Support Level | $118.07 | $180.98 |
| Resistance Level | $133.62 | $191.50 |
| Average True Range (ATR) | 3.45 | 3.14 |
| MACD | 0.76 | 0.13 |
| Stochastic Oscillator | 82.67 | 48.05 |
Citigroup is a global financial powerhouse that orchestrates the movement of $5 trillion in daily transaction volume, serving as the essential connective tissue for the world's most complex multinational corporations. The firm remains a leader on the global stage, servicing 90% of the Fortune 500 through a proprietary network that includes direct membership to over 270 cash-clearing centers and a footprint that spans 94 countries. After a checkered history operating as an overly complex, disjointed firm, steps have been taken to streamline operations, resulting in organization across five segments: services, markets, banking, wealth, and US personal banking.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.